No CrossRef data available.
Article contents
Recombinant factor VIIa as a rescue therapy in severe haemoptysis in a patient with a Fontan circulation
Published online by Cambridge University Press: 11 September 2017
Abstract
We describe the successful use of recombinant factor VIIa (rFVIIa) in the control of massive haemoptysis in a 17-year-old patient with a Fontan circulation. The patient was intubated and ventilated in the ICU with deteriorating gas exchange. Conventional methods to control the haemoptysis were ineffective, and rFVIIa was successfully administered as a rescue therapy. rFVIIa is a powerful pro-thrombotic agent, which is only licensed in haemophiliacs with acquired inhibitors to anticoagulation. It has been used off-license in the treatment of massive haemorrhage, although a Cochrane review did not show any significant benefit; however, it may have a role as a rescue therapy where alternatives options have been exhausted after careful risk–benefit analysis.
Keywords
- Type
- Brief Report
- Information
- Copyright
- © Cambridge University Press 2017